Glycomics

Comprehensive Biotechnology, Second Edition

Volumn 1, Issue , 2011, Pages 427-446

  Cosgrave, E F J ^a   Struwe, W B ^a   Kattla, J J ^a   Campbell, M P ^b   Wormald, M R ^c   Rudd, P M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bioinformatics; Bioproduction; Glyco analytics; Glycomics; Glycoprotein therapeutics; Glycosylation; High performance liquid chromatography; Mass spectrometry

Indexed keywords

EID: 85012845160     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-08-088504-9.00051-9     Document Type: Chapter

References (145)

1. Opat A.S., van Vliet C., Gleeson P.A. Trafficking and localisation of resident Golgi glycosylation enzymes. Biochimie 2001, 83(8):763-773.
2. Ungar D., Oka T., Brittle E.E., et al. Characterization of a mammalian Golgi-localized protein complex, COG, that is required for normal Golgi morphology and function. Journal of Cell Biology 2002, 157(3):405-415.
3. Lehle L., Strahl S., Tanner W. Protein glycosylation, conserved from yeast to man: A model organism helps elucidate congenital human diseases. Angewandte Chemie International Edition in English 2006, 45(41):6802-6818.
4. Freeze H.H., Westphal V. Balancing N-linked glycosylation to avoid disease. Biochimie 2001, 83(8):791-799.
5. Altmann F., Fabini G., Ahorn H., Wilson I.B. Genetic model organisms in the study of N-glycans. Biochimie 2001, 83(8):703-712.
6. Huffaker T.C., Robbins P.W. Temperature-sensitive yeast mutants deficient in asparagine-linked glycosylation. Journal of Biological Chemistry 1982, 257(6):3203-3210.
7. Jones J., Krag S.S., Betenbaugh M.J. Controlling N-linked glycan site occupancy. Biochimica et Biophysica Acta 2005, 1726(2):121-137.
8. Hossler P., Mulukutla B.C., Hu W.S. Systems analysis of N-glycan processing in mammalian cells. PLoS One 2007, 2(1):e713.
9. Elsner M., Hashimoto H., Nilsson T. Cisternal maturation and vesicle transport: Join the band wagon! (Review). Molecular Membrane Biology 2003, 20(3):221-229.
10. Van den Steen P., Rudd P.M., Dwek R.A., et al. Cytokine and protease glycosylation as a regulatory mechanism in inflammation and autoimmunity. Advances in Experimental Medicine and Biology 1998, 435:133-143.
11. Watson M., Rudd P.M., Bland M., et al. Sugar printing rheumatic diseases: A potential method for disease differentiation using immunoglobulin G oligosaccharides. Arthritis and Rheumatism 1999, 42(8):1682-1690.
12. Rudd P.M., Elliott T., Cresswell P., et al. Glycosylation and the immune system. Science 2001, 291(5512):2370-2376.
13. Ritchie G.E., Moffatt B.E., Sim R.B., et al. Glycosylation and the complement system. Chemical Reviews 2002, 102(2):305-20-19.
14. Opdenakker G., Dillen C., Fiten P., et al. Remnant epitopes, autoimmunity and glycosylation. Biochimica et Biophysica Acta 2006, 1760(4):610-615.
15. Radcliffe C.M., Arnold J.N., Suter D.M., et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. Journal of Biological Chemistry 2007, 282(10):7405-7415.
16. Saldova R., Royle L., Radcliffe C.M., et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007, 17(12):1344-1356.
17. Abd Hamid U.M., Royle L., Saldova R., et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008, 18(12):1105-1118.
18. Saldova R., Wormald M.R., Dwek R.A., Rudd P.M. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Disease Markers 2008, 25(4-5):219-232.
19. Royle L., Campbell M.P., Radcliffe C.M., et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Analytical Biochemistry 2008, 376(1):1-12.
20. Anumula K.R. Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates. Analytical Biochemistry 2006, 350(1):1-23.
21. Anumula K.R. High-sensitivity and high-resolution methods for glycoprotein analysis. Analytical Biochemistry 2000, 283(1):17-26.
22. Guile G.R., Rudd P.M., Wing D.R., et al. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Analytical Biochemistry 1996, 240(2):210-226.
23. Tangvoranuntakul P., Gagneux P., Diaz S., et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proceedings of the National Academy of Sciences 2003, 100(21):12045-12050.
24. Beavis R.C., Chait B.T. High-accuracy molecular mass determination of proteins using matrix-assisted laser desorption mass spectrometry. Analytical Chemistry 1990, 62(17):1836-1840.
25. Beavis R.C., Chait B.T. Rapid, sensitive analysis of protein mixtures by mass spectrometry. Proceedings of the National Academy of Sciences 1990, 87(17):6873-6877.
26. Harvey D.J. Structural determination of N-linked glycans by matrix-assisted laser desorption/ionization and electrospray ionization mass spectrometry. Proteomics 2005, 5(7):1774-1786.
27. Kang P., Mechref Y., Klouckova I., Novotny M.V. Solid-phase permethylation of glycans for mass spectrometric analysis. Rapid Communications in Mass Spectrometry 2005, 19(23):3421-3428.
28. Ashline D.J., Lapadula A.J., Liu Y.H., et al. Carbohydrate structural isomers analyzed by sequential mass spectrometry. Analytical Chemistry 2007, 79(10):3830-3842.
29. Harvey D.J. Fragmentation of negative ions from carbohydrates: Part 3. Fragmentation of hybrid and complex N-linked glycans. Journal of the American Society for Mass Spectrometry 2005, 16(5):647-659.
30. Harvey D.J. Fragmentation of negative ions from carbohydrates: Part 2. Fragmentation of high-mannose N-linked glycans. Journal of the American Society for Mass Spectrometry 2005, 16(5):631-646.
31. Harvey D.J. Fragmentation of negative ions from carbohydrates: Part 1. Use of nitrate and other anionic adducts for the production of negative ion electrospray spectra from N-linked carbohydrates. Journal of the American Society for Mass Spectrometry 2005, 16(5):622-630.
32. Packer N.H., von der Lieth C.W., Aoki-Kinoshita K.F., et al. Frontiers in glycomics: Bioinformatics and biomarkers in disease. An NIH white paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006). Proteomics 2008, 8(1):8-20.
33. Herget S., Ranzinger R., Maass K., Lieth C.W. GlycoCT - a unifying sequence format for carbohydrates. Carbohydrate Research 2008, 343(12):2162-2171.
34. Ceroni A., Dell A., Haslam S.M. The GlycanBuilder: A fast, intuitive and flexible software tool for building and displaying glycan structures. Source Code for Biology and Medicine 2007, 2:3.
35. Campbell M.P., Royle L., Radcliffe C.M., et al. GlycoBase and autoGU: Tools for HPLC-based glycan analysis. Bioinformatics 2008, 24(9):1214-1216.
36. Hossler P., Khattak S.F., Li Z.J. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 2009, 19(9):936-949.
37. Walsh G., Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nature Biotechnology 2006, 24(10):1241-1252.
38. Jefferis R. Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action. Trends in Pharmacological Sciences 2009, 30(7):356-362.
39. Li H., d'Anjou M. Pharmacological significance of glycosylation in therapeutic proteins. Current Opinion in Biotechnology 2009, 20(6):678-684.
40. Aggarwal S. What's fueling the biotech engine - 2008. Nature Biotechnology 2009, 27(11):987-993.
41. Aggarwal S. What's fueling the biotech engine - 2007. Nature Biotechnology 2008, 26(11):1227-1233.
42. Sairam M.R., Krishnamurthy H. The role of follicle-stimulating hormone in spermatogenesis: Lessons from knockout animal models. Archives of Medical Research 2001, 32(6):601-608.
43. Simoni M., Weinbauer G.F., Gromoll J., Nieschlag E. Role of FSH in male gonadal function. Annales D Endocrinologie (Paris) 1999, 60(2):102-106.
44. Robker R.L., Richards J.S. Hormone-induced proliferation and differentiation of granulosa cells: A coordinated balance of the cell cycle regulators cyclin D2 and p27Kip1. Molecular Endocrinology 1998, 12(7):924-940.
45. Waterstone J., Parsons J., Bolton V. Elective transfer of two embryos. Lancet 1991, 337(8747):975-976.
46. Giudice E., Crisci C., Eshkol A., Papoian R. Infertility: Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: Characterization of non-gonadotrophin proteins. Human Reproduction 1994, 9(12):2291-2299.
47. Ulloa-Aguirre A., Timossi C. Structure-function relationship of follicle-stimulating hormone and its receptor. Human Reproduction 1998, 4(3):260-283.
48. Bishop L.A., Robertson D.M., Cahir N., Schofield P.R. Specific roles for the asparagine-linked carbohydrate residues of recombinant human follicle stimulating hormone in receptor binding and signal transduction. Molecular Endocrinology 1994, 8(6):722-731.
49. Creus S., Chaia Z., Pellizzari E.H., et al. Human FSH isoforms: Carbohydrate complexity as determinant of in-vitro bioactivity. Molecular and Cellular Endocrinology 2001, 174(1-2):41-49.
50. D'Antonio M., Borrelli F., Datola A., et al. Biological characterization of recombinant human follicle stimulating hormone isoforms. Human Reproduction 1999, 14(5):1160-1167.
51. Miller C., Ulloa-Aguirre A., Hyland L., Chappel S. Pituitary follicle-stimulating hormone heterogeneity: Assessment of biologic activities of each follicle-stimulating hormone form. Fertility and Sterility 1983, 40(2):242-247.
52. Brines M., Patel N.S., Villa P., et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(31):10925-10930.
53. Fantacci M., Bianciardi P., Caretti A., et al. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(46):17531-17536.
54. Mennini T., De Paola M., Bigini P., et al. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Molecular Medicine 2006, 12(7-8):153-160.
55. Leist M., Ghezzi P., Grasso G., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305(5681):239-242.
56. Fukuda M.N., Sasaki H., Lopez L., Fukuda M. Survival of recombinant erythropoietin in the circulation: The role of carbohydrates. Blood 1989, 73(1):84-89.
57. Delorme E., Lorenzini T., Giffin J., et al. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 1992, 31(41):9871-9876.
58. Elliott S., Chang D., Delorme E., et al. Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin. Journal of Biological Chemistry 2004, 279(16):16854-16862.
59. Elliott S., Egrie J., Browne J., et al. Control of rHuEPO biological activity: The role of carbohydrate. Experimental Hematology 2004, 32(12):1146-1155.
60. Erbayraktar S., Grasso G., Sfacteria A., et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proceedings of the National Academy of Sciences 2003, 100(11):6741-6746.
61. Chiba Y., Akeboshi H. Glycan engineering and production of "Humanized" glycoprotein in yeast cells. Biological and Pharmaceutical Bulletin 2009, 32(5):786-795.
62. Pastores G.M., Meere P.A. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Current Opinion in Rheumatology 2005, 17(1):70-78.
63. Pastores G.M., Weinreb N.J., Aerts H., et al. Therapeutic goals in the treatment of Gaucher disease. Seminars in Hematology 2004, 41(4 supplement 5):4-14.
64. Elstein D., Zimran A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics 2009, 3:407-417.
65. Schiffmann R., Murray G.J., Treco D., et al. Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(1):365-370.
66. Van den Hout J.M., Kamphoven J.H., Winkel L.P., et al. Long-term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk. Pediatrics 2004, 113(5):e448-e457.
67. Pastores G.M. Laronidase (Aldurazyme): Enzyme replacement therapy for mucopolysaccharidosis type I. Expert Opinion in Biological Therapy 2008, 8(7):1003-1009.
68. Clarke L.A. Idursulfase for the treatment of mucopolysaccharidosis II. Expert Opinion in Pharmacotherapy 2008, 9(2):311-317.
69. Hopwood J.J., Bate G., Kirkpatrick P. Galsulfase. Nature Reviews Drug Discovery 2006, 5(2):101-102.
70. Brady R.O., Gal A.E., Bradley R.M., et al. Enzymatic defect in Fabry's disease. Ceramide trihexosidase deficiency. New England Journal of Medicine 1967, 276(21):1163-1167.
71. Chiba Y., Sakuraba H., Kotani M., et al. Production in yeast of α-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. Glycobiology 2002, 12(12):821-828.
72. Odani T., Shimma Y., Wang X.H., Jigami Y. Mannosylphosphate transfer to cell wall mannan is regulated by the transcriptional level of the MNN4 gene in Saccharomyces cerevisiae. FEBS Letters 1997, 420(2-3):186-190.
73. Gray P.W., Goeddel D.V. Structure of the human immune interferon gene. Nature 1982, 298(5877):859-863.
74. Schoenborn J.R., Wilson C.B., Frederick W.A. Regulation of interferon-γ during innate and adaptive immune responses. Advances in Immunology 2007, 41-101. Academic Press.
75. Rinderknecht E., O'Connor B.H., Rodriguez H. Natural human interferon-γ. Complete amino acid sequence and determination of sites of glycosylation. Journal of Biological Chemistry 1984, 259(11):6790-6797.
76. Mutsaers J.H.G.M., Kamerling J.P., Devos R., et al. Structural studies of the carbohydrate chains of human γ-interferon. European Journal of Biochemistry 1986, 156(3):651-654.
77. Yamamoto S., Hase S., Yamauchi H., et al. Studies on the sugar chains of interferon-γ from human peripheral-blood lymphocytes. Journal of Biochemistry 1989, 105(6):1034-1039.
78. Yamamoto S., Hase S., Fukuda S., et al. Structures of the sugar chains of interferon-γ produced by human myelomonocyte cell line HBL-38. Journal of Biochemistry 1989, 105(4):547-555.
79. Sareneva T., Pirhonen J., Cantell K., et al. Role of N-glycosylation in the synthesis, dimerization and secretion of human interferon-γ. Biochemical Journal 1994, 303(Pt 3):831-840.
80. Sareneva T., Pirhonen J., Cantell K., Julkunen I. N-Glycosylation of human interferon-γ: Glycans at Asn-25 are critical for protease resistance. Biochemical Journal 1995, 308(Pt 1):9-14.
81. Meager A., Leist T. Antigenic characteristics of glycosylated natural and unglycosylated recombinant human gamma-interferon. Journal of Interferon Research 1986, 6(3):225-232.
82. Sareneva T., Cantell K., Pyhala L., et al. Effect of carbohydrates on the pharmacokinetics of human interferon-γ. Journal of Interferon Research 1993, 13(4):267-269.
83. Lamotte D., Buckberry L., Monaco L., et al. Na-butyrate increases the production and α2,6-sialylation of recombinant interferon-γ expressed by α2,6-sialyltransferase engineered CHO cells. Cytotechnology 1999, 29(1):55-64.
84. Walsh G. Biopharmaceutical benchmarks 2006. Nature Biotechnology 2006, 24(7):769-776.
85. Bruhns P., Iannascoli B., England P., et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113(16):3716-3725.
86. Nezlin R., Ghetie V. Interactions of immunoglobulins outside the antigen-combining site. Advances in Immunology 2004, 82:155-215.
87. Roopenian D.C., Akilesh S. FcRn: The neonatal Fc receptor comes of age. Nature Reviews Immunology 2007, 7(9):715-725.
88. Goebl N.A., Babbey C.M., Datta-Mannan A., et al. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Molecular Biology of the Cell 2008, 19(12):5490-5505.
89. Tao M.H., Morrison S.L. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. Journal of Immunology 1989, 143(8):2595-2601.
90. Hobbs S.M., Jackson L.E., Hoadley J. Interaction of aglycosyl immunoglobulins with the IgG Fc transport receptor from neonatal rat gut: Comparison of deglycosylation by tunicamycin treatment and genetic engineering. Molecular Immunology 1992, 29(7-8):949-956.
91. Mimura Y., Ashton P.R., Takahashi N., et al. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. Journal of Immunological Methods 2007, 326(1-2):116-126.
92. Malhotra R., Wormald M.R., Rudd P.M., et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nature Medicine 1995, 1(3):237-243.
93. Arnold J.N., Dwek R.A., Rudd P.M., Sim R.B. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunology Letters 2006, 106(2):103-110.
94. Rademacher T.W. Glycosylation as a factor affecting product consistency. Biologicals 1993, 21(2):103-104.
95. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313(5787):670-673.
96. Anthony R.M., Wermeling F., Karlsson M.C.I., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proceedings of the National Academy of Sciences 2008, 105(50):19571-19578.
97. Jones A.J.S., Papac D.I., Chin E.H., et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and Cynomolgus monkeys. Glycobiology 2007, 17(5):529-540.
98. Bragonzi A., Distefano G., Buckberry L.D., et al. A new Chinese hamster ovary cell line expressing α2,6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins. Biochimica et Biophysica Acta 2000, 1474(3):273-282.
99. Erbayraktar S., Grasso G., Sfacteria A., et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(11):6741-6746.
100. Hamilton S.R., Davidson R.C., Sethuraman N., et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 2006, 313(5792):1441-1443.
101. Okazaki A., Shoji-Hosaka E., Nakamura K., et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. Journal of Molecular Biology 2004, 336(5):1239-1249.
102. Ferrara C., Stuart F., Sondermann P., et al. The Carbohydrate at FcγRIIIa Asn-162: An element required for high affinity binding to non-fucosylated IgG glycoforms. Journal of Biological Chemistry 2006, 281(8):5032-5036.
103. Shibata-Koyama M., Iida S., Okazaki A., et al. The N-linked oligosaccharide at FcγRIIIa Asn-45: An inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology 2009, 19(2):126-134.
104. Naoko Y.-O., Satoko K., Miho I.-U., et al. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnology and Bioengineering 2004, 87(5):614-622.
105. Schachter H. Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. Biochemistry and Cell Biology 1986, 64(3):163-181.
106. Bergwerff A.A., Stroop C.J., Murray B., et al. Variation in N-linked carbohydrate chains in different batches of two chimeric monoclonal IgG1 antibodies produced by different murine SP2/0 transfectoma cell subclones. Glycoconjugate Journal 1995, 12(3):318-330.
107. Lifely M.R., Hale C., Boyce S., et al. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995, 5(8):813-822.
108. Umana P., Jean-Mairet J., Moudry R., et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnology 1999, 17(2):176-180.
109. Ferrara C., Brünker P., Suter T., et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous β1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnology and Bioengineering 2006, 93(5):851-861.
110. Masarik M., Kizek R., Kramer K.J., et al. Application of avidin-biotin technology and adsorptive transfer stripping square-wave voltammetry for detection of DNA hybridization and avidin in transgenic avidin maize. Analytical Chemistry 2003, 75(11):2663-2669.
111. Ann R.K., Elizabeth E.H., Derrick R.W., et al. Production and purification of two recombinant proteins from transgenic corn. Biotechnology Progress 1998, 14(1):149-155.
112. Parmenter D.L., Boothe J.G., van Rooijen G.J., et al. Production of biologically active hirudin in plant seeds using oleosin partitioning. Plant Molecular Biology 1995, 29(6):1167-1180.
113. Bardor M., Faveeuw C., Fitchette A.C., et al. Immunoreactivity in mammals of two typical plant glyco-epitopes, core α(1,3)-fucose and core xylose. Glycobiology 2003, 13(6):427-434.
114. Bencurova M., Hemmer W., Focke-Tejkl M., et al. Specificity of IgG and IgE antibodies against plant and insect glycoprotein glycans determined with artificial glycoforms of human transferrin. Glycobiology 2004, 14(5):457-466.
115. Rayon C., Cabanes-Macheteau M., Loutelier-Bourhis C., et al. Characterization of N-glycans from Arabidopsis. Application to a fucose-deficient mutant. Plant Physiology 1999, 119(2):725-734.
116. Frey A.D., Karg S.R., Kallio P.T. Expression of rat β(1,4)-N-acetylglucosaminyltransferase III in Nicotiana tabacum remodels the plant-specific N-glycosylation. Plant Biotechnology Journal 2009, 7(1):33-48.
117. Koprivova A., Stemmer C., Altmann F., et al. Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans. Plant Biotechnology Journal 2004, 2(6):517-523.
118. Weise A., Altmann F., Rodriguez-Franco M., et al. High-level expression of secreted complex glycosylated recombinant human erythropoietin in the Physcomitrella Δfuc-t -Δxyl-t mutant. Plant Biotechnology Journal 2007, 5(3):389-401.
119. Lerouge P., Cabanes-Macheteau M., Rayon C., et al. N-Glycoprotein biosynthesis in plants: Recent developments and future trends. Plant Molecular Biology 1998, 38(1-2):31-48.
120. Altmann F., Schwihla H., Staudacher E., et al. Insect cells contain an unusual, membrane-bound β-N-acetylglucosaminidase probably involved in the processing of protein N-glycans. Journal of Biological Chemistry 1995, 270(29):17344-17349.
121. Wagner R., Liedtke S., Kretzschmar E., et al. Elongation of the N-glycans of fowl plague virus hemagglutinin expressed in Spodoptera frugiperda (Sf9) cells by coexpression of human β1,2-N-acetylglucosaminyltransferase I. Glycobiology 1996, 6(2):165-175.
122. Hollister J.R., Jarvis D.L. Engineering lepidopteran insect cells for sialoglycoprotein production by genetic transformation with mammalian β1,4-galactosyltransferase and α2,6-sialyltransferase genes. Glycobiology 2001, 11(1):1-9.
123. Hollister J.R., Conradt H., Jarvis D.L. Evidence for a sialic acid salvaging pathway in lepidopteran insect cells. Glycobiology 2003, 13(6):487-495.
124. Lawrence S.M., Huddleston K.A., Tomiya N., et al. Cloning and expression of human sialic acid pathway genes to generate CMP-sialic acids in insect cells. Glycoconjugate Journal 2001, 18(3):205-213.
125. Aumiller J.J., Hollister J.R., Jarvis D.L. A transgenic insect cell line engineered to produce CMP-sialic acid and sialylated glycoproteins. Glycobiology 2003, 13(6):497-507.
126. Herscovics A., Orlean P. Glycoprotein biosynthesis in yeast. FASEB Journal 1993, 7(6):540-550.
127. 2) sugar chains in Saccharomyces cerevisiae. Journal of Biological Chemistry 1998, 273(41):26298-26304.
128. Herscovics A. Structure and function of Class I α1,2-mannosidases involved in glycoprotein synthesis and endoplasmic reticulum quality control. Biochimie 2001, 83(8):757-762.
129. Choi B.K., Bobrowicz P., Davidson R.C., et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proceedings of the National. Academy of Sciences 2003, 100(9):5022-5027.
130. Schwientek T., Narimatsu H., Ernst J.F. Golgi localization and in vivo activity of a mammalian glycosyltransferase (human 1,4-galactosyltransferase) in yeast. Journal of Biological Chemistry 1996, 271(7):3398-3405.
131. Vervecken W., Kaigorodov V., Callewaert N., et al. In vivo synthesis of mammalian-like, hybrid-type N-glycans in Pichia pastoris. Applied and Environmental Microbiology 2004, 70(5):2639-2646.
132. Bobrowicz P., Davidson R.C., Li H., et al. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: Production of complex humanized glycoproteins with terminal galactose. Glycobiology 2004, 14(9):757-766.
133. Figueroa B., Ailor E., Osborne D., et al. Enhanced cell culture performance using inducible anti-apoptotic genes E1B-19K and Aven in the production of a monoclonal antibody with Chinese hamster ovary cells. Biotechnology and Bioengineering 2007, 97(4):877-892.
134. Lee Y.Y., Wong K.T., Tan J., et al. Overexpression of heat shock proteins (HSPs) in CHO cells for extended culture viability and improved recombinant protein production. Journal of Biotechnology 2009, 143(1):34-43.
135. Peng R.W., Fussenegger M. Molecular engineering of exocytic vesicle traffic enhances the productivity of Chinese hamster ovary cells. Biotechnology and Bioengineering 2009, 102(4):1170-1181.
136. Florin L., Pegel A., Becker E., et al. Heterologous expression of the lipid transfer protein CERT increases therapeutic protein productivity of mammalian cells. Journal of Biotechnology 2009, 141(1-2):84-90.
137. Bork K., Horstkorte R., Weidemann W. Increasing the sialylation of therapeutic glycoproteins: The potential of the sialic acid biosynthetic pathway. Journal of Pharmaceutical Sciences 2009, 98(10):3499-3508.
138. Jeong Y.T., Choi O., Son Y.D., et al. Enhanced sialylation of recombinant erythropoietin in genetically engineered Chinese-hamster ovary cells. Biotechnology and Applied Biochemistry 2009, 52(Pt 4):283-291.
139. Butler M. Animal cell cultures: Recent achievements and perspectives in the production of biopharmaceuticals. Applied Microbiology and Biotechnology 2005, 68(3):283-291.
140. Chung C.H., Mirakhur B., Chan E., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. New England Journal of Medicine 2008, 358(11):1109-1117.
141. Muchmore E.A., Milewski M., Varki A., Diaz S. Biosynthesis of N-glycolyneuraminic acid. The primary site of hydroxylation of N-acetylneuraminic acid is the cytosolic sugar nucleotide pool. Journal of Biological Chemistry 1989, 264(34):20216-20223.
142. Baker K.N., Rendall M.H., Hills A.E., et al. Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. Biotechnology and Bioengineering 2001, 73(3):188-202.
143. Alex Z., Rosa H. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002, 9(6):376-381.
144. Flesher A.R., Marzowski J., Wang W.-C., Raff H.V. Fluorophore-labeled carbohydrate analysis of immunoglobulin fusion proteins: Correlation of oligosaccharide content with in vivo clearance profile. Biotechnology and Bioengineering 1995, 46(5):399-407.
145. Covic A., Cannata-Andia J., Cancarini G., et al. Biosimilars and biopharmaceutricals: What the nephrologists need to know - a position paper by the ERA-EDTA Council. Nephrology Dialysis Transplantation 2008, 23:3731-3737.